BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 26852128)

  • 41. Clinical Features and Current Optimal Management of Natural Killer/T-Cell Lymphoma.
    Makita S; Tobinai K
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):239-253. PubMed ID: 28340876
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Appropriate timing to perform an interim
    Wang R; Zhang Y; Fan Q; Jiang M; Zou L; Su M
    Ann Hematol; 2024 Mar; 103(3):885-892. PubMed ID: 38030892
    [TBL] [Abstract][Full Text] [Related]  

  • 43. "Sandwich" Chemotherapy (CT) with Radiotherapy (RT) improves outcomes in patients with stage IE/IIE extranodal natural killer (NK)/T-cell Lymphomas.
    Zhang J; Zhu MY; Wang L; Wang H; Wang WD; Geng QR; Lu Y
    Asian Pac J Cancer Prev; 2013; 14(7):4061-6. PubMed ID: 23991953
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The clinical study of extranodal natural killer cell lymphoma, nasal type.
    Gui W; Zhao Z; Shen Q; Wang T; Yang B; He J; Li X; Hou S; Zhang L; Zhang Q; Su L
    Med Oncol; 2011 Dec; 28 Suppl 1():S367-72. PubMed ID: 21128014
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The prognostic nutritional index predicts survival for patients with extranodal natural killer/T cell lymphoma, nasal type.
    Chen KL; Liu YH; Li WY; Chen J; Gu YK; Geng QR; Jiang WQ; Huang HQ; Lin TY; Xia ZJ; Cai QQ
    Ann Hematol; 2015 Aug; 94(8):1389-400. PubMed ID: 25869028
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Prognostic factors of primary non-Hodgkin's lymphoma of the nasal cavity--a report of 129 cases].
    Yao B; Li YX; Fang H; Jin J; Liu XF; Yu ZH
    Ai Zheng; 2006 Apr; 25(4):465-70. PubMed ID: 16613682
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prognostic factors and treatment outcome in early stage nasal NK/T cell lymphoma].
    Yao B; Li YX; Fang H; Yu ZH; Jin J; Liu XF
    Zhonghua Xue Ye Xue Za Zhi; 2006 Apr; 27(4):222-5. PubMed ID: 16875550
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
    Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
    J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcome after hematopoietic stem cell transplantation in patients with extranodal natural killer/T-Cell lymphoma, nasal type: A French study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).
    Philippe Walter L; Couronné L; Jais JP; Nguyen PD; Blaise D; Pigneux A; Socié G; Thieblemont C; Bachy E; Fegueux N; Chevallier P; Mohty M; Yakoub-Agha I; Peffault de Latour R; Jaccard A; Hermine O;
    Am J Hematol; 2021 Jul; 96(7):834-845. PubMed ID: 33864708
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Prognosis and treatment strategies of primary B-cell and NK/T-cell nasopharyngeal non-Hodgkin's lymphoma at early stage].
    Zou GR; Zhang YJ; Xie FY; Zheng W; Li HX; Xia YF; Lin TY; Lu TX
    Ai Zheng; 2006 Dec; 25(12):1543-9. PubMed ID: 17166383
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.
    Li P; Jiang L; Zhang X; Liu J; Wang H
    BMC Cancer; 2014 Nov; 14():890. PubMed ID: 25429803
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary spinal natural killer/T-cell lymphoma successfully treated with concurrent chemoradiotherapy and autologous stem cell transplantation.
    Kim KT; Kim YB; Kim HJ; Cha YJ; Lee SJ; Park E
    Spine (Phila Pa 1976); 2012 May; 37(10):E629-32. PubMed ID: 22089400
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prognostic significance of Ki-67 antigen expression in extranodal natural killer/T-cell lymphoma, nasal type.
    Jiang L; Li P; Wang H; Liu J; Zhang X; Qiu H; Zhang B
    Med Oncol; 2014 Oct; 31(10):218. PubMed ID: 25204411
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.
    Kim SJ; Yoon DH; Jaccard A; Chng WJ; Lim ST; Hong H; Park Y; Chang KM; Maeda Y; Ishida F; Shin DY; Kim JS; Jeong SH; Yang DH; Jo JC; Lee GW; Choi CW; Lee WS; Chen TY; Kim K; Jung SH; Murayama T; Oki Y; Advani R; d'Amore F; Schmitz N; Suh C; Suzuki R; Kwong YL; Lin TY; Kim WS
    Lancet Oncol; 2016 Mar; 17(3):389-400. PubMed ID: 26873565
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel treatment for early-stage nasal natural killer/T-cell lymphoma: intra-maxillary arterial infusion chemotherapy with concomitant radiotherapy.
    Takahara M; Nagato T; Kishibe K; Ueda S; Komabayashi Y; Yamashina M; Takahashi K; Harabuchi Y
    Hematol Oncol; 2017 Jun; 35(2):158-162. PubMed ID: 26563973
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Current management of nasal NK/T-cell lymphoma.
    Au WY
    Oncology (Williston Park); 2010 Apr; 24(4):352-8. PubMed ID: 20464847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
    Qi F; Chen B; Wang J; Lin X; Qi S; Yang J; Zhou S; Wang S; Gui L; Fang H; Liu P; Song Y; Yang S; Li Y; Dong M
    Leuk Lymphoma; 2019 Nov; 60(11):2679-2688. PubMed ID: 31298062
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Clinical features and prognosis of nasal type NK/T cell lymphoma].
    Zhang YJ; Hu WH; Liu H; Cheng EC; Ren ZM; Xia YF; Cui NJ
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):50-3. PubMed ID: 16737622
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy (18)F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type.
    Jiang C; Zhang X; Jiang M; Zou L; Su M; Kosik RO; Tian R
    Ann Nucl Med; 2015 Jun; 29(5):442-51. PubMed ID: 25801633
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
    Kim SJ; Yang DH; Kim JS; Kwak JY; Eom HS; Hong DS; Won JH; Lee JH; Yoon DH; Cho J; Nam TK; Lee SW; Ahn YC; Suh C; Kim WS
    Ann Hematol; 2014 Nov; 93(11):1895-901. PubMed ID: 24947798
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.